Q3 EBITDA Surge Supports Cost Story, but Leverage and Cash Flow Still Need Watching

What happened

Dow's Q3 2026 results showed a 79% year-over-year jump in operating EBITDA to $1.55 billion, driven by price increases and cost initiatives, which management attributes to the Transform to Outperform program. The stock has declined 18% despite this improvement, reflecting concerns about margin normalization and demand in a still-oversupplied petrochemical market. Management also guided for $1.3 billion in incremental 2027 earnings from transformation and asset actions, suggesting the cost-cutting story is gaining traction. However, the article's bullish stance contrasts with earlier caution that free cash flow remains pressured by high capex and restructuring costs. The market appears to be debating whether the EBITDA improvement is sustainable or merely a cyclical bounce amplified by temporary price gains.

Implication

The Q3 EBITDA beat is a positive signal that the Transform to Outperform program is delivering, but the 18% stock decline shows the market is still skeptical about sustainability given global overcapacity. With management guiding for $1.3 billion incremental 2027 earnings, the medium-term cost savings could meaningfully improve profitability, yet the balance sheet remains highly leveraged with net debt/EBITDA still elevated. Investors should monitor cash flow conversion and restructuring cash costs over the next few quarters to assess whether the company can generate enough free cash flow to reduce debt without further shareholder-friendly actions. The article's call to buy relies on continued margin recovery and cost delivery, which are not guaranteed given cyclical risks and new capacity coming online. Until there is clear evidence of sustained EBITDA above $5 billion and positive free cash flow, a wait-and-see approach may still be prudent despite the recent operational improvement.

Thesis delta

The original WAIT thesis anticipated needing 2-3 quarters of demonstrated EBITDA uplift; Q3 2026 provides the first strong confirmation of cost-led improvement. However, the article's BUY stance may be premature because free cash flow and leverage have not yet improved decisively. The thesis shifts from waiting for initial evidence to evaluating whether the improvement is durable enough to support the stock's valuation, with a bias toward upgrading to BUY if cash flow and debt metrics strengthen over the next two quarters.